Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.18)
# 388
Out of 4,784 analysts
224
Total ratings
35.61%
Success rate
22.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Overweight | $67 → $123 | $71.99 | +70.86% | 6 | Mar 27, 2025 | |
| XFOR X4 Pharmaceuticals | Reiterates: Overweight | $3 | $0.25 | +1,100.00% | 4 | Mar 26, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $11.50 | +160.87% | 5 | Mar 20, 2025 | |
| SRPT Sarepta Therapeutics | Reiterates: Overweight | $163 | $70.41 | +131.50% | 15 | Mar 19, 2025 | |
| MREO Mereo BioPharma Group | Reiterates: Overweight | $7 | $2.30 | +204.35% | 10 | Mar 18, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $99 → $132 | $52.36 | +152.10% | 8 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | $25 | $7.85 | +218.47% | 1 | Mar 12, 2025 | |
| ADMA ADMA Biologics | Reiterates: Overweight | $25 | $20.26 | +23.40% | 9 | Mar 4, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $118 | $37.82 | +212.00% | 18 | Feb 26, 2025 | |
| SUPN Supernus Pharmaceuticals | Reiterates: Neutral | $36 | $32.29 | +11.49% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $113 | $54.24 | +108.33% | 18 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $19.93 | +236.18% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $8.43 | +149.11% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $8.08 | +258.91% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $3.02 | +462.91% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.50 | +433.33% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $12.47 | +365.12% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $25 | $17.88 | +39.82% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.81 | +291.46% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $1.93 | +262.69% | 15 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $4.97 | +262.17% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.87 | +648.66% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.96 | +563.27% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.01 | - | 3 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.81 | +1,060.22% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $0.49 | +1,124.49% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.32 | +1,415.15% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $2.56 | +798.44% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.33 | +67,569.17% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.80 | +5,025.00% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $3.42 | +11,595.91% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $4.12 | +1,963.11% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,500 | $0.48 | +729,066.67% | 1 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.33 | +2,743.60% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.13 | +3,882.30% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $0.80 | +1,275.86% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.27 | +4,624.41% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.31 | +6,770.23% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.59 | +158,390.57% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.57 | +28,019.51% | 1 | Jan 9, 2020 |
Soleno Therapeutics
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $71.99
Upside: +70.86%
X4 Pharmaceuticals
Mar 26, 2025
Reiterates: Overweight
Price Target: $3
Current: $0.25
Upside: +1,100.00%
Capricor Therapeutics
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $11.50
Upside: +160.87%
Sarepta Therapeutics
Mar 19, 2025
Reiterates: Overweight
Price Target: $163
Current: $70.41
Upside: +131.50%
Mereo BioPharma Group
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.30
Upside: +204.35%
Disc Medicine
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $52.36
Upside: +152.10%
Zevra Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: $25
Current: $7.85
Upside: +218.47%
ADMA Biologics
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $20.26
Upside: +23.40%
Ultragenyx Pharmaceutical
Feb 26, 2025
Reiterates: Overweight
Price Target: $118
Current: $37.82
Upside: +212.00%
Supernus Pharmaceuticals
Feb 26, 2025
Reiterates: Neutral
Price Target: $36
Current: $32.29
Upside: +11.49%
Feb 3, 2025
Maintains: Overweight
Price Target: $76 → $113
Current: $54.24
Upside: +108.33%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $19.93
Upside: +236.18%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $8.43
Upside: +149.11%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $8.08
Upside: +258.91%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $3.02
Upside: +462.91%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $1.50
Upside: +433.33%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $12.47
Upside: +365.12%
Dec 10, 2024
Maintains: Neutral
Price Target: $15 → $25
Current: $17.88
Upside: +39.82%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.81
Upside: +291.46%
Nov 14, 2024
Reiterates: Overweight
Price Target: $7
Current: $1.93
Upside: +262.69%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $4.97
Upside: +262.17%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.87
Upside: +648.66%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.96
Upside: +563.27%
Sep 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.01
Upside: -
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.81
Upside: +1,060.22%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.49
Upside: +1,124.49%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.32
Upside: +1,415.15%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.56
Upside: +798.44%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.33
Upside: +67,569.17%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.80
Upside: +5,025.00%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $3.42
Upside: +11,595.91%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $4.12
Upside: +1,963.11%
Feb 28, 2022
Initiates: Overweight
Price Target: $3,500
Current: $0.48
Upside: +729,066.67%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.33
Upside: +2,743.60%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.13
Upside: +3,882.30%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $0.80
Upside: +1,275.86%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.27
Upside: +4,624.41%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.31
Upside: +6,770.23%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.59
Upside: +158,390.57%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.57
Upside: +28,019.51%